DelveInsight’s, “Chronic Myelomonocytic Leukemia Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Chronic Myelomonocytic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Chronic Myelomonocytic Leukaemia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Chronic Myelomonocytic Leukaemia Pipeline Outlook

 

Key Takeaways from the Chronic Myelomonocytic Leukaemia Pipeline Report

• In October 2024:- Taiho Oncology Inc.- A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
• In October 2024:- Douglas Tremblay- This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who have previously been treated with a hypomethylating agent (HMA) must have received ≤ 1 cycle.
• DelveInsight’s Chronic Myelomonocytic Leukaemia pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Myelomonocytic Leukaemia treatment.
• The leading Chronic Myelomonocytic Leukaemia Companies such as Kura Oncology, Immune-Onc Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, AbbVie, Nerviano Medical Sciences, Newave Pharmaceuticals, Amgen, and others.
• Promising Chronic Myelomonocytic Leukaemia Therapies such as S227928, Venetoclax, Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine, Tuspetinib, and others.

 

Stay ahead with the most recent pipeline outlook for Chronic Myelomonocytic Leukaemia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Myelomonocytic Leukaemia Treatment Drugs

 

Chronic Myelomonocytic Leukaemia Emerging Drugs Profile

• Ruxolitinib: Incyte Corporation

Ruxolitinib is a selective Janus kinase (JAK) inhibitor primarily used for treating myelofibrosis and polycythemia vera, and it has shown promise in chronic myelomonocytic leukemia (CMML). In CMML, ruxolitinib targets the JAK1 and JAK2 pathways, which are crucial for cytokine signaling and hematopoiesis. The mechanism of action involves inhibiting the dysregulated JAK-STAT signaling pathway, which is often activated in myeloproliferative neoplasms, leading to abnormal cell proliferation and inflammation. Clinical trials have demonstrated that ruxolitinib can reduce splenomegaly and improve disease-related symptoms in CMML patients, particularly those with high symptom burdens or splenomegaly, by decreasing inflammatory cytokines and promoting hematologic improvement. Currently, the drug is in Phase II stage of its development for the treatment of CMML.

• NMS-03592088: Nerviano Medical Sciences

NMS-03592088 is a novel, potent inhibitor of FLT3, KIT and CSF1R, all relevant targets in AML. NMS-03592088 showed superior preclinical activity compared with approved FLT3 inhibitors in different FLT3-driven models. In addition, NMS-03592088 is active on FLT3 gatekeeper mutation F691L causing resistance to f irst generation FLT3 inhibitors. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Chronic Myelomonocytic Leukemia (CMML).

• IO-202: Immune-Onc Therapeutics

IO-202 is a first-in-class IgG1 antibody with specific, high-affinity binding to LILRB4 and depletes LILRB4 positive cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. As such, IO-202 is a targeted therapy with broad potential in blood cancers and autoimmune and inflammatory diseases.The U.S. Food and Drug Administration granted IO-202 Fast Track Designations for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and relapsed or refractory CMML, respectively. The FDA has also granted IO-202 Orphan Drug Designations for the treatment of AML and CMML, respectively. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CMML.

 

Explore groundbreaking therapies and clinical trials in the Chronic Myelomonocytic Leukaemia Pipeline. Access DelveInsight’s detailed report now! @ New Chronic Myelomonocytic Leukaemia Drugs

 

Chronic Myelomonocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Chronic Myelomonocytic Leukaemia Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Unveil the future of Chronic Myelomonocytic Leukaemia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Chronic Myelomonocytic Leukaemia Market Drivers and Barriers

 

Scope of the Chronic Myelomonocytic Leukaemia Pipeline Report

• Coverage- Global
• Chronic Myelomonocytic Leukaemia Companies- Kura Oncology, Immune-Onc Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, AbbVie, Nerviano Medical Sciences, Newave Pharmaceuticals, Amgen, and others.
• Chronic Myelomonocytic Leukaemia Therapies- S227928, Venetoclax, Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine, Tuspetinib, and others.
• Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Chronic Myelomonocytic Leukaemia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Chronic Myelomonocytic Leukaemia Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Myelomonocytic Leukemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Myelomonocytic Leukemia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Mid Stage Products (Phase II)
10. Ruxolitinib: Incyte Corporation
11. Early Stage Products (Phase I)
12. IO-202: Immune-Onc Therapeutics
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Chronic Myelomonocytic Leukemia Key Companies
17. Chronic Myelomonocytic Leukemia Key Products
18. Chronic Myelomonocytic Leukemia- Unmet Needs
19. Chronic Myelomonocytic Leukemia- Market Drivers and Barriers
20. Chronic Myelomonocytic Leukemia- Future Perspectives and Conclusion
21. Chronic Myelomonocytic Leukemia Analyst Views
22. Chronic Myelomonocytic Leukemia Key Companies
23. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/